title: Should you thrombolyse all or any stroke patients with baseline National Institutes of Health stroke scale scores < or = 5?
authors: Calgary Stroke Program, Department of Clinical Neurosciences, University of Calgary, Calgary, Alta., Canada. nikolai.steffenhagen@Medizin.Uni-Leipzig.de
authors: Nikolai
authors: N
authors: Steffenhagen
authors: Michael D
authors: MD
authors: Hill
authors: Alexandre Y
authors: AY
authors: Poppe
authors: Alastair M
authors: AM
authors: Buchan
authors: Shelagh B
authors: SB
authors: Coutts
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D020300:Intracranial Hemorrhages / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D016017:Odds Ratio; D018579:Patient Selection; D012042:Registries; D018570:Risk Assessment; D012720:Severity of Illness Index; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014481:United States
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator